SARS‐CoV‐2 receptor ACE2 protein expression in serum is significantly associated with age

Ana B. Pavel(University of Mississippi), Emma Guttman‐Yassky(Icahn School of Medicine at Mount Sinai)

Allergy

July 29, 2020

10.1111/all.14522

Cited by 37

Related Papers

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

|New England Journal of Medicine|2016|2k

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

|British Journal of Dermatology|2020|590

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

|The Lancet|2021|538

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis

|JAMA Dermatology|2019|505

Non-lesional Atopic Dermatitis Skin Is Characterized by Broad Terminal Differentiation Defects and Variable Immune Abnormalities

|Journal of Allergy and Clinical Immunology|2011|457